Spironolactone: Nursing Drug Guide, Hyperkalemia Risk & Hold Rules
This aldosterone antagonist saves lives in heart failure—but potassium can climb silently when renal function slips, ACE inhibitors stack on the MAR, or a patient still takes salt substitutes. Check potassium before every dose change, not only on admission.
Spironolactone retains potassium. Labeling warns that hyperkalemia risk rises with impaired renal function, potassium supplements, potassium-containing salt substitutes, ACE inhibitors, ARBs, NSAIDs, heparin, and trimethoprim. Monitor serum potassium within one week of initiation or titration and regularly thereafter. If hyperkalemia occurs, decrease the dose or discontinue spironolactone and treat hyperkalemia per protocol—do not assume a mild BMP bump is harmless on telemetry.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, review the latest basic metabolic panel—especially potassium and creatinine—and scan the MAR for ACE inhibitors, ARBs, potassium products, and NSAIDs. Hold spironolactone when potassium is above protocol limits or creatinine jumps with poor urine output, then notify the prescriber or pharmacist. Pair therapy with intake and output monitoring and teach patients to avoid potassium salt substitutes unless directed.
Most common brand names
Aldactone is the long-standing U.S. brand for spironolactone tablets. Carospir is an oral suspension formulation. Generic spironolactone tablets are supplied as 25 mg, 50 mg, and 100 mg strengths per U.S. labeling—verify strength on every administration pass; these are not interchangeable without a prescriber order.
Fixed-dose combination products containing spironolactone plus hydrochlorothiazide exist in some markets; confirm whether the MAR lists a single combination tablet versus separate agents. Heart-failure regimens often pair spironolactone with a loop diuretic such as furosemide—both may be intentional; still reconcile potassium risk across the full diuretic plan.
Why we give it — Indications
U.S. prescribing information lists spironolactone as an aldosterone antagonist for NYHA Class III–IV heart failure with reduced ejection fraction (to increase survival, manage edema, and reduce heart-failure hospitalization), as add-on therapy for hypertension, for edema in cirrhosis or nephrotic syndrome when other measures are inadequate, and for primary hyperaldosteronism (short-term preoperative or long-term maintenance when surgery is not suitable).
| Use | Detail |
|---|---|
| Heart failure (HFrEF) | Usually given with other heart-failure therapies; RALES trial mean dose ~26 mg/day with mortality benefit when potassium and renal criteria met |
| Hypertension (add-on) | For patients not adequately controlled on other agents; typical range 25–100 mg/day in single or divided doses |
| Edema (cirrhosis / nephrotic syndrome) | Initiate in hospital when cirrhotic; may counteract hypokalemia from other diuretics while retaining potassium |
| Primary hyperaldosteronism | 100–400 mg/day preoperatively or for long-term maintenance at lowest effective individualized dose |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Spironolactone and active metabolites (including canrenone) competitively block aldosterone receptors at the distal convoluted renal tubule. Sodium and water are excreted while potassium is retained—the opposite electrolyte pattern from loop and thiazide diuretics. It acts as both a diuretic and antihypertensive agent and may be used alone or with more proximal-acting diuretics. In heart failure, it counteracts secondary aldosteronism from volume depletion caused by other diuretic therapy.
Dosing overview
Take consistently with respect to food—labeling notes food increases bioavailability. Individualize to the lowest effective dose and renal/potassium status.
Renal impairment: Substantially renally excreted; greater adverse-reaction risk and hyperkalemia risk—monitor potassium closely. Consider every-other-day dosing when eGFR 30–50 mL/min/1.73 m² per heart-failure initiation guidance.
Hepatic impairment: In cirrhosis with ascites, initiate in hospital; fluid/electrolyte shifts may worsen hepatic encephalopathy or coma—start lowest dose and titrate slowly.
Pediatrics: Safety and effectiveness not established per labeling.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.
Onset, peak, and duration
- Peak plasma: Spironolactone ~2.6 hours; active metabolite canrenone ~4.3 hours in healthy volunteers per labeling
- Food effect: Food increases bioavailability (~95% AUC increase)—take consistently with regard to meals
- Half-life: Spironolactone ~1.4 hours; canrenone ~16.5 hours; clinical potassium effect may persist beyond parent drug half-life
- Metabolism/excretion: Extensively metabolized; metabolites excreted primarily in urine and secondarily in bile—relevant when renal function declines
Before you give it — Safety check
Pretreatment checks
- Latest BMP: potassium (must not be elevated), sodium, creatinine, BUN, glucose, bicarbonate/CO2
- Review serum creatinine trend and urine output—hyperkalemia risk rises as renal function falls
- Scan MAR and home med list for ACE inhibitors/ARBs, potassium supplements, salt substitutes, NSAIDs, heparin, trimethoprim, lithium, digoxin
- Confirm tablet strength (25, 50, or 100 mg) matches order; verify not contraindicated with eplerenone on MAR
Contraindications
- Hyperkalemia
- Addison disease
- Concomitant use of eplerenone
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| ACE inhibitors / ARBs | Concomitant use may cause severe hyperkalemia; discontinue potassium supplements in heart failure patients starting spironolactone per labeling | Recheck potassium when ACE inhibitor or ARB dose changes; hold spironolactone for rising K+ above protocol |
| Potassium supplements / salt substitutes | May lead to severe hyperkalemia when combined with spironolactone | Confirm potassium chloride or OTC substitutes are intentionally ordered; teach patients to avoid unless prescribed |
| NSAIDs | May reduce diuretic, natriuretic, and antihypertensive effect; also raise potassium risk | Assess edema and BP response; screen OTC NSAID use at admission and discharge |
| Digoxin | Spironolactone interferes with some digoxin immunoassays—increased apparent digoxin level | Coordinate with lab/pharmacy on assay method; do not assume level reflects true exposure; monitor clinically |
| Lithium | Reduced renal clearance increases lithium toxicity risk | Monitor lithium levels when co-administered per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: 25 mg, 50 mg, and 100 mg strengths. May take with or without food but should be taken consistently with respect to food per labeling.
- Give at the same time each day relative to meals once a routine is established
- Many regimens use morning dosing to align with diuretic schedules—follow MAR exactly
- Perform medication reconciliation at transitions—home spironolactone plus inpatient ACE inhibitor changes are a common hyperkalemia trigger
- Pair administration with scheduled BMP timing after initiation or dose titration (within one week per labeling)
Labeling states that in general, discontinue potassium supplementation in heart failure patients who start spironolactone. Nurses should question duplicate potassium sources—scheduled potassium chloride, salt substitutes, and high-potassium diet orders—unless the prescriber documents an intentional plan with monitoring.
Expected therapeutic response
- Gradual reduction in edema, weight, or ascites when used for fluid overload—use edema assessment and daily weights
- Blood pressure reduction when used as antihypertensive add-on therapy (may take weeks of titration)
- In heart failure, improved symptom control and reduced hospitalization risk when combined with guideline-directed therapy—monitor for hypotension or over-diuresis when loop diuretics continue
- Stable serum potassium within prescriber targets—not a higher K+ that is dismissed as “expected”
Red flags — Stop and act
Hyperkalemia may present with vague symptoms or sudden arrhythmia—especially when ACE inhibitors, ARBs, and spironolactone overlap in heart failure.
- Serum potassium above prescriber or protocol hold limit, or upward trend across serial BMP values
- Palpitations, new bradycardia, widened QRS, or peaked T waves on telemetry when potassium is elevated or trending up
- Muscle weakness, flaccid paralysis, paresthesias, or reported inability to lift limbs—hyperkalemia neuromuscular signs
- Marked creatinine/BUN rise with oliguria—worsening renal function increases potassium retention
- Symptomatic hypotension, dehydration, or confusion in cirrhosis suggesting encephalopathy or excessive diuresis
- Severe hypersensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (reported per labeling)
Adverse effects
| Adverse effect | Notes (labeling) | Nursing response |
|---|---|---|
| Hyperkalemia | Primary labeled warning; risk increases with renal impairment and potassium-raising drugs | Hold dose; notify prescriber/pharmacist; repeat BMP; initiate hyperkalemia protocol per facility |
| Gynecomastia | Most common labeled adverse reaction; dose-dependent; ~9% of males at mean ~26 mg/day in RALES; usually reversible | Document onset; support body-image concerns; prescriber may adjust therapy |
| Hypotension / renal dysfunction | Excessive diuresis may cause dehydration, hypotension, worsening renal function—especially with ACE inhibitors/ARBs or nephrotoxic drugs | Monitor volume status, orthostatic blood pressure, creatinine, and I&O |
| Electrolyte/metabolic effects | May also cause hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis, hyperglycemia, hyperuricemia | Trend BMP and glucose periodically per labeling |
| GI effects | Gastric bleeding, ulceration, gastritis, nausea, vomiting, diarrhea reported | Assess for GI bleed; differentiate from electrolyte-related nausea |
| Endocrine/reproductive | Decreased libido, erectile dysfunction, menstrual irregularities, breast pain reported | Nonjudgmental teaching; involve prescriber for intolerable symptoms |
| Hepatic encephalopathy/coma | Fluid/electrolyte shifts in cirrhosis with ascites may precipitate impaired neurological function | Monitor mental status; initiate in hospital per labeling for cirrhotic edema |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Acute overdose may cause drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea per labeling. Hyponatremia, hyperkalemia, or hepatic coma may occur in patients with severe liver disease. Hyperkalemia may occur especially with renal impairment.
Antidote
Not specified in the reviewed prescribing information — labeling states there is no specific antidote. Treatment is supportive.
Management per labeling
- Induce vomiting or evacuate stomach by lavage when clinically appropriate
- Maintain hydration, electrolyte balance, and vital functions with close monitoring
- Discontinue spironolactone if hyperkalemia develops in renal impairment
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Spironolactone vs spironolactone/hydrochlorothiazide (Aldactazide and generics) — combination products add thiazide diuretic effect; never substitute without pharmacist verification
- Spironolactone vs eplerenone — both are aldosterone antagonists; labeling contraindicates concomitant use
- 25 mg vs 50 mg vs 100 mg tablets — triple-check strength; scored 50 mg and 100 mg tablets can be split only per order
- Aldactone brand name — verbal orders may be misheard; confirm generic name and strength in writing
- Duplicate potassium-sparing therapy — home spironolactone plus new inpatient order; perform medication reconciliation at every transition
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food consistency | Take with or without food but keep the same pattern—food markedly increases absorption |
| Potassium orders | Question scheduled potassium chloride when spironolactone starts in heart failure unless prescriber documents plan |
| ACE inhibitor changes | Labeling directs potassium recheck when ACE inhibitor or ARB therapy is altered |
| Gynecomastia counseling | Warn males that breast tissue changes may occur weeks to months after start—usually reversible |
| Digoxin levels | Assay interference possible—coordinate with lab before reacting to isolated level changes |
| Ask pharmacy when | Unclear dose in renal impairment, combination diuretic questions, or suspected hyperkalemia on MAR |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment | Greater hyperkalemia risk; drug substantially renally excreted—monitor potassium closely per labeling |
| Chronic kidney disease | Consider every-other-day dosing when eGFR 30–50; avoid or hold when potassium elevated |
| Older adults | Higher likelihood of decreased renal function and hyperkalemia with polypharmacy (ACE inhibitors, ARBs, NSAIDs) |
| Hepatic cirrhosis / ascites | Initiate in hospital; sudden fluid/electrolyte shifts may precipitate encephalopathy or coma; start lowest dose and titrate slowly |
| Heart failure on ACE inhibitor/ARB | Standard triple therapy increases survival but demands serial potassium monitoring—RALES excluded K+ >5 mEq/L and Cr >2.5 mg/dL at baseline |
| Pregnancy | Labeling advises avoiding spironolactone or counseling on potential risk to male fetus due to anti-androgenic properties; animal data show feminization of male fetuses |
| Lactation | Spironolactone not detected in milk; active metabolite canrenone present in low amounts in limited reports—consider benefits of breastfeeding versus maternal need and potential infant effects |
| Pediatrics | Safety and effectiveness not established per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serum potassium within one week of initiation or titration and regularly thereafter; more often with renal impairment or potassium-raising drugs
- Serum electrolytes, uric acid, and blood glucose periodically per labeling
- Creatinine, BUN, volume status, blood pressure, weight, and I&O during active diuresis
- Telemetry or rhythm assessment when potassium is borderline or rising
- Mental status in cirrhosis; gynecomastia or menstrual changes when counseling males and females
Document
- Dose, strength, time, indication, and whether taken with food per established routine
- Latest BMP values, especially potassium and creatinine, and any hold parameters triggered
- Concurrent ACE inhibitor/ARB, potassium supplement, NSAID, or digoxin use reviewed
- Patient teaching on salt substitutes, OTC NSAIDs, and hyperkalemia symptoms
Patient teaching
- Do not use potassium supplements or salt substitutes containing potassium unless your prescriber specifically directs you to—spironolactone retains potassium
- Report muscle weakness, heaviness in legs, palpitations, skipped heartbeats, nausea, or unusual fatigue promptly
- Ask before taking OTC ibuprofen or other NSAIDs—they can affect kidneys and potassium
- Take spironolactone the same way each day with respect to meals once you establish a routine
- Males: breast tenderness or enlargement can occur and is usually reversible—tell your care team rather than stopping abruptly
- Keep scheduled lab appointments for potassium and kidney function checks after dose changes
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Serum potassium above institutional hold parameters or any documented hyperkalemia contraindication
- Known spironolactone allergy or serious hypersensitivity reaction
- Addison disease or concurrent eplerenone on the MAR
- Marked creatinine/BUN rise with oliguria suggesting worsening renal function during therapy
- Symptomatic hypotension, dehydration, or acute mental status change in cirrhosis
- New serious skin reaction (SJS/TEN/DRESS) or anaphylaxis per labeling
Labeling directs dose reduction or discontinuation when hyperkalemia occurs. Hold parameters may vary by institutional protocol—follow prescriber orders and facility policy.
Clinical practice integration and workflow
Spironolactone is guideline-directed therapy in HFrEF—but the same drug that reduces mortality can cause preventable hyperkalemia when nurses treat potassium checks as optional after day three.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right potassium on the most recent BMP
- Scan MAR for ACE inhibitor/ARB, potassium products, NSAIDs, and duplicate aldosterone antagonists
- After any spironolactone initiation or dose change, confirm potassium is scheduled within one week per labeling
- Verify tablet strength (25, 50, or 100 mg) before every administration
2. High-alert and safety badge
Not a universal high-alert drug, but potassium-retaining diuretic with fatal hyperkalemia potential—requires BMP discipline comparable to high-risk electrolyte drugsLabeling hyperkalemia warning applies to all indications—not only heart failure.
3. Clinical workflow: hold and question rules
- If potassium trends upward across two BMP values, hold the next dose and page the team before giving another potassium-sparing dose
- If ACE inhibitor dose increases while spironolactone continues, clarify repeat potassium timing
- Never restart home potassium supplements automatically at discharge when spironolactone is new on the regimen
4. Critical teach-back questions
- “What salt substitutes or potassium products must you avoid while taking this medication?” (Patient should name potassium-containing salt substitutes and unprescribed supplements.)
- “What symptoms should you report right away?” (Patient should name muscle weakness, palpitations, severe fatigue, or nausea suggesting hyperkalemia.)
5. Care coordination
Pharmacist: Interaction review with ACE inhibitors/ARBs, potassium product reconciliation, digoxin assay considerations, and renal-dose guidance
Prescriber: Notify for hyperkalemia, rising creatinine with oliguria, intolerable gynecomastia, hypotension, or need to adjust diuretic regimen in cirrhosis
🧠 Quick mental checklist
- What is the latest potassium—and is it trending up?
- Are ACE inhibitors, ARBs, potassium supplements, or salt substitutes on the MAR?
- Was BMP drawn within one week of the last dose change?
- Any muscle weakness, palpitations, or telemetry changes?
- Did I teach the patient about potassium salt substitutes and OTC NSAIDs?
Spironolactone NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for spironolactone hyperkalemia risk using a tabbed heart-failure case (MAR, labs, vitals, nursing notes), then priority action, cue-recognition SATA, potassium trend SATA, matrix urgency sorting, potassium-supplement judgment, and overdose cloze—with explicit evaluate outcomes after the team adjusts therapy.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Spironolactone 25 mg PO daily — started 5 days ago; dose due 0900
- Lisinopril 20 mg PO daily — increased from 10 mg yesterday per cardiology
- Furosemide 40 mg PO daily — given 0700
- Potassium chloride 20 mEq PO BID — continued from admission order
- Digoxin 0.125 mg PO daily — given 0700
- Admission K+ 4.3 mEq/L; day 3: 4.8; today 5.6 mEq/L (BMP 0730)
- Creatinine 1.1 → 1.38 mg/dL over 5 days; BUN 24 → 38 mg/dL
- eGFR ~52 mL/min/1.73 m² on admission
- BP 108/62; HR 54 (baseline HR low 60s)
- Telemetry: intermittent PVCs; peaked T waves noted at 0830
- Reports mild leg heaviness when walking to bathroom
- Weight stable; net negative 0.8 L yesterday on I&O sheet
- 68-year-old with HFrEF admitted for volume overload; lungs clearer after diuresis
- Patient uses potassium-based salt substitute at home—brought to bedside in personal bag
- 0845: nurse preparing 0900 spironolactone after reviewing case tabs
- Pharmacy note on chart: reconcile potassium supplementation with new aldosterone antagonist
Answer key & rationale
Frequently asked questions
What should I check before giving spironolactone?
Review the latest basic metabolic panel—especially serum potassium, creatinine, BUN, sodium, and glucose—confirm the patient is not already hyperkalemic, and scan the MAR for ACE inhibitors, ARBs, potassium supplements, salt substitutes, NSAIDs, digoxin, and lithium. Match tablet strength (25, 50, or 100 mg) to the order, verify renal function and volume status, and ensure potassium was checked within one week of any recent initiation or dose change per labeling.
When should nurses hold spironolactone?
Hold and contact the prescriber or pharmacist when serum potassium is above protocol limits or labeling contraindicates therapy, creatinine rises sharply with oliguria, the patient has symptomatic hypotension or dehydration, there is known hypersensitivity, Addison disease is documented, or eplerenone is co-ordered. Labeling directs dose reduction or discontinuation when hyperkalemia occurs—do not give the next dose while potassium remains elevated unless the prescriber clarifies the plan.
Why is hyperkalemia the main spironolactone danger with ACE inhibitors?
Spironolactone is a potassium-sparing aldosterone antagonist that retains potassium while promoting sodium and water loss. ACE inhibitors and ARBs also reduce aldosterone effects and can raise potassium. Labeling warns that concomitant potassium supplements, salt substitutes, or other potassium-raising drugs may cause severe hyperkalemia. In heart failure patients starting spironolactone, potassium supplementation is generally discontinued, and nurses should recheck potassium when ACE inhibitor or ARB therapy changes.
How often should potassium be monitored on spironolactone?
Prescribing information directs monitoring serum potassium within one week of initiation or titration and regularly thereafter. More frequent monitoring is needed with impaired renal function or when spironolactone is given with other drugs that increase potassium. In severe heart failure trials, labs were obtained every four weeks initially, then at longer intervals—follow prescriber orders and institutional protocol for repeat BMP timing.
Is there an antidote for spironolactone overdose?
No specific antidote is listed in the reviewed prescribing information. Acute overdose may cause drowsiness, confusion, rash, nausea, vomiting, dizziness, or diarrhea; hyperkalemia may occur especially with renal impairment. Treatment is supportive—maintain hydration, electrolyte balance, and vital functions; discontinue spironolactone if hyperkalemia develops. Contact local poison control or medical toxicology services per facility protocol for significant overdose.
References
- U.S. National Library of Medicine. SPIRONOLACTONE tablet — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c23b6b9b-aec3-48a8-a518-76e4097f6479
- U.S. National Library of Medicine. ALDACTONE (spironolactone) tablet — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc
- Joint Formulary Committee. Spironolactone monograph. BNF (NICE).https://bnf.nice.org.uk/drugs/spironolactone/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.